Experimental eye drug aims to halt rare blindness

NCT ID NCT06852963

First seen Jan 04, 2026 · Last updated Jun 09, 2026 · Updated 25 times

Summary

This study tests an experimental drug called VP-001 for people with a rare inherited eye disease that causes vision loss. The drug is injected into the eye to see if it is safe and can slow down damage to the retina. About 17 adults who have already received VP-001 in earlier studies will receive two different doses over 26 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Bascom Palmer Eye Institute - University of Miami

    Miami, Florida, 33136, United States

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

  • Casey Eye Institute - OHSU

    Portland, Oregon, 97239, United States

  • Kellogg Eye Center - University of Michigan

    Ann Arbor, Michigan, 48105, United States

  • Retina Foundation of the Southwest

    Dallas, Texas, 75231, United States

  • University of Florida College of Medicine

    Jacksonville, Florida, 32209, United States

Conditions

Explore the condition pages connected to this study.